These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 29121061

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L.
    Lancet; 2014 Mar 22; 383(9922):1049-58. PubMed ID: 24360369
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS, Wilairatana P, Tang DB, Heppner DG, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S.
    Clin Infect Dis; 2004 Oct 15; 39(8):1095-103. PubMed ID: 15486831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    Warrasak S, Euswas A, Fukuda MM, Ittiverakul M, Miller RS, Krudsood S, Ohrt C.
    Int Ophthalmol; 2019 Aug 15; 39(8):1767-1782. PubMed ID: 30269312
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
    Beck HP, Wampfler R, Carter N, Koh G, Osorio L, Rueangweerayut R, Krudsood S, Lacerda MV, Llanos-Cuentas A, Duparc S, Rubio JP, Green JA.
    J Infect Dis; 2016 Mar 01; 213(5):794-9. PubMed ID: 26500351
    [Abstract] [Full Text] [Related]

  • 13. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
    Anjum MU, Naveed AK, Mahmood SN, Naveed OK.
    Travel Med Infect Dis; 2020 Mar 01; 36():101576. PubMed ID: 32036012
    [Abstract] [Full Text] [Related]

  • 14. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
    Kitchener S, Nasveld P, Edstein MD.
    Am J Trop Med Hyg; 2007 Mar 01; 76(3):494-6. PubMed ID: 17360873
    [Abstract] [Full Text] [Related]

  • 15. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
    Vélez ID, Hien TT, Green JA, Martin A, Sharma H, Rousell VM, Breton JJ, Ernest TB, Rolfe K, Taylor M, Mohamed K, Jones SW, Chau NH, Hoa NT, Duparc S, Tan LK, Goyal N.
    Lancet Child Adolesc Health; 2022 Feb 01; 6(2):86-95. PubMed ID: 34871570
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    Milligan R, Daher A, Villanueva G, Bergman H, Graves PM.
    Cochrane Database Syst Rev; 2020 Aug 19; 8():CD012656. PubMed ID: 32816320
    [Abstract] [Full Text] [Related]

  • 18. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
    Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ.
    PLoS Negl Trop Dis; 2018 Apr 19; 12(4):e0006440. PubMed ID: 29677199
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
    Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD.
    Trans R Soc Trop Med Hyg; 2008 Nov 19; 102(11):1095-101. PubMed ID: 18541280
    [Abstract] [Full Text] [Related]

  • 20. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
    Brito M, Rufatto R, Murta F, Sampaio V, Balieiro P, Baía-Silva D, Castro V, Alves B, Alencar A, Duparc S, Grewal Daumerie P, Borghini-Fuhrer I, Jambert E, Peterka C, Edilson Lima F, Carvalho Maia L, Lucena Cruz C, Maciele B, Vasconcelos M, Machado M, Augusto Figueira E, Alcirley Balieiro A, Menezes A, Ataídes R, Batista Pereira D, Lacerda M.
    Lancet Glob Health; 2024 Mar 19; 12(3):e467-e477. PubMed ID: 38365417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.